Toor Divya Kumari, Degu Amsalu, Karimi Peter N
School of Pharmacy and Health Sciences, Department of Pharmaceutics and Pharmacy Practice, United States International University-Africa, Nairobi, Kenya.
Department of Pharmacology, Clinical Pharmacy and Pharmacy Practices, Faculty of Health Sciences, University of Nairobi, Nairobi, Kenya.
Cancer Rep (Hoboken). 2025 Jan;8(1):e70112. doi: 10.1002/cnr2.70112.
In developing countries, the treatment outcomes of Burkitt lymphoma are poor due to the poorly equipped healthcare systems. In addition, there is limited comprehensive data within the African continent, including Kenya, about the outcomes of treatment for this cancer.
To assess treatment outcomes and variables associated with an increased risk of death from disease progression or treatment-related toxicities among Burkitt lymphoma pediatric patients at the Kenyatta National Hospital (KNH).
A retrospective one-arm cohort study was conducted to examine the treatment outcomes of pediatric patients with Burkitt lymphoma. All eligible Burkitt lymphoma pediatric patients treated between January 1, 2016 and December 31, 2022 were included. The patients were retrospectively monitored from the initial cancer diagnosis until either death or the last follow-up appointment visit in the facility. Data analysis of factors associated with treatment and disease progression-related death was carried out using the SPSS version 29.0 software. Kaplan-Meier survival and Cox regression analyses were employed to determine the survival time and predictors of mortality, respectively. The median age of the patients at diagnosis was 6 years (range: 3-13 years). The majority of patients were diagnosed with Stage IV disease accounting for 46.7% of all patients. Of the 75 patients studied, 24% (18) of them were died. The 5-year overall survival rate was 70%, and most patients had stable disease during the follow-up period. Patients with Stage IV disease who were treated with full-fuse chemotherapy were 19.2 (AHR = 19.2, 95% CI = 5.2-48.5, p < 0.001) and 7.4 times (AHR = 7.4, 95% CI = 2.2-19.9, p = 0.003) more hazard of dying as compared to patients without metastasis and received a combination of radiation and reduced-dose chemotherapy, respectively. However, the age, gender, stage of cancer, histological type of cancer, and co-morbidity were not significant predictors of survival. Because of the retrospective nature of the study design, the data accuracy relied on the proper documentation of medical records in the study setting.
The 5-year overall survival rate among pediatric burkitt's lymphoma patients was above average as compared to other African countries. Most patients had reduced tumor size and stable disease during the follow-up period. Metastases and full-fuse chemotherapy were significant predictors of mortality.
在发展中国家，由于医疗保健系统设备简陋，伯基特淋巴瘤的治疗效果不佳。此外，在非洲大陆，包括肯尼亚，关于这种癌症治疗结果的综合数据有限。
评估肯雅塔国家医院（KNH）伯基特淋巴瘤儿科患者疾病进展或治疗相关毒性导致死亡风险增加的治疗结果及相关变量。
进行了一项回顾性单臂队列研究，以检查伯基特淋巴瘤儿科患者的治疗结果。纳入了2016年1月1日至2022年12月31日期间接受治疗的所有符合条件的伯基特淋巴瘤儿科患者。从最初的癌症诊断开始对患者进行回顾性监测，直至死亡或在该机构进行最后一次随访就诊。使用SPSS 29.0软件对与治疗和疾病进展相关死亡的因素进行数据分析。分别采用Kaplan-Meier生存分析和Cox回归分析来确定生存时间和死亡率预测因素。患者诊断时的中位年龄为6岁（范围：3 - 13岁）。大多数患者被诊断为IV期疾病，占所有患者的46.7%。在研究的75例患者中，24%（18例）死亡。5年总生存率为70%，大多数患者在随访期间病情稳定。与无转移且接受放疗和减量化疗联合治疗的患者相比，接受全剂量化疗的IV期疾病患者死亡风险分别高19.2倍（风险比[AHR]=19.2，95%置信区间[CI]=5.2 - 48.5，p<0.001）和7.4倍（AHR = 7.4，95% CI = 2.2 - 19.9，p = 0.003）。然而，年龄、性别、癌症分期、癌症组织学类型和合并症不是生存的显著预测因素。由于研究设计的回顾性性质，数据准确性依赖于研究环境中医疗记录的妥善记录。
与其他非洲国家相比，伯基特淋巴瘤儿科患者的5年总生存率高于平均水平。大多数患者在随访期间肿瘤大小减小且病情稳定。转移和全剂量化疗是死亡率的显著预测因素。
